专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2773669B1 LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6 (LRP6) - HALF LIFE EXTENDER CONSTRUCTS 有权
标题翻译：低密度脂蛋白相关蛋白6（LRP6） - 半衰期延长结构
公开(公告)号：EP2773669B1
公开(公告)日：2018-03-28
申请号：EP12791031.3
申请日：2012-11-02
申请人： Novartis AG
发明人： JENKINS, David , LEI, Ming , LOEW, Andreas , ZHOU, Li
IPC分类号： C07K16/28 , A61K39/395 , C07K14/76 , C07K14/765 , C07K14/775 , C07K16/30 , C07K16/46 , A61K39/00 , A61K38/38 , A61K47/68
CPC分类号： A61K47/48415 , A61K38/385 , A61K39/39558 , A61K47/6811 , A61K2039/505 , C07K14/76 , C07K14/765 , C07K14/775 , C07K16/28 , C07K16/30 , C07K16/46 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C12N2740/15041 , Y10S424/809
摘要： The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.

2. 发明公开

EP3290442A1 LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6 (LRP6) HALF-LIFE EXTENDER CONSTRUCTS 审中-实审
标题翻译：低密度脂蛋白相关蛋白6（LRP6）半衰期延长结构
公开(公告)号：EP3290442A1
公开(公告)日：2018-03-07
申请号：EP17196699.7
申请日：2012-11-02
申请人： Novartis AG
发明人： JENKINS, David , LEI, Ming , LOEW, Andreas , ZHOU, Li
IPC分类号： C07K16/28 , A61K39/395 , C07K14/76 , C07K14/765 , C07K14/775 , C07K16/30 , C07K16/46 , A61K38/38 , A61K47/68 , A61K39/00
CPC分类号： A61K47/48415 , A61K38/385 , A61K39/39558 , A61K47/6811 , A61K2039/505 , C07K14/76 , C07K14/765 , C07K14/775 , C07K16/28 , C07K16/30 , C07K16/46 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2317/94 , C07K2319/30 , C07K2319/31 , C12N2740/15041 , Y10S424/809
摘要： The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit.
摘要翻译：本发明涉及与LRP6受体结合的LRP6构建体。 LRP6构建体包含至少一个LRP6结合部分和半衰期延长剂分子，使得LRP6构建体抑制Wnt信号传导途径而不增强Wnt信号。 LRP6构建体也具有增加的半衰期以提供更多治疗益处。

3. 发明公开

EP3119425A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
标题翻译：调节剂CHIMÄRER抗生素
公开(公告)号：EP3119425A1
公开(公告)日：2017-01-25
申请号：EP15764851.0
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译：提供与可调节嵌合抗原受体（RCAR），天然杀伤细胞受体CAR（NKR-CAR）和可调节NKR-CAR（RNKR-CAR）有关的组合物和方法，其中RCAR或RNKR-CAR的细胞内信号传导或增殖可以控制以优化RCAR / NKR-CAR或RNKR-CAR表达细胞的使用以提供免疫应答。可以将细胞工程化以表达RNKR-CAR或表达RCAR和NKR-CAR（例如抑制性NKR-CAR）。例如，RCAR或RNKR-CAR可以包含二聚转换开关，其在二聚化分子的存在下可以将细胞内信号结构域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域，或共刺激ECD域。 RCAR或RNKR-CAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

4. 发明公开

EP3087101A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
标题翻译：调节剂CHIMÄRER抗生素
公开(公告)号：EP3087101A1
公开(公告)日：2016-11-02
申请号：EP14872734.0
申请日：2014-12-19
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Brogdon, Jennifer , Engels, Boris , GLASS, David, Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , Milone, Michael C. , MURPHY, Leon , SELLERS, William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
发明人： BROGDON, Jennifer , ENGELS, Boris , GLASS, David Jonathan , GRANDA, Brian , HASTEWELL, John , LOEW, Andreas , MANNICK, Joan , MILONE, Michael , MURPHY, Leon , SELLERS,William Raj , SONG, Huijuan , VASH, Brian Edward , WEILER, Jan , WU, Qilong , ZHOU, Li
IPC分类号： C07K19/00 , C12N5/0783
CPC分类号： C07K16/2863 , A61K31/436 , A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K14/71 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/41 , C07K2319/43 , C07K2319/70 , C12N9/1205 , C12N9/90 , C12Y502/00
摘要： Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.
摘要翻译：提供了与可调节嵌合抗原受体（RCAR）相关的组合物和方法，其中可以控制RCAR的细胞内信号传导或增殖以优化使用表达RCAR的细胞以提供免疫应答。例如，RCAR可以包含二聚转换开关，其在存在二聚化分子时可以将细胞内信号转导域偶联到细胞外识别元件，例如抗原结合结构域，抑制性反配体结合结构域或共刺激ECD结构域。 RCAR可以被设计成包括对所需抗原靶特异性并用于治疗疾病的合适的抗原结合结构域。

5. 发明公开

EP2643353A1 MULTISPECIFIC MOLECULES 审中-公开
标题翻译：多特异性分子
公开(公告)号：EP2643353A1
公开(公告)日：2013-10-02
申请号：EP11784717.8
申请日：2011-11-22
申请人： Novartis AG
发明人： LEI, Ming , LI, Jing , ZHOU, Li , ZHU, Zhenping
IPC分类号： C07K16/28 , C07K16/32
CPC分类号： C07K16/468 , C07K16/00 , C07K16/2863 , C07K16/32 , C07K2317/31 , C07K2317/53 , C07K2317/60 , C07K2317/64
摘要： The present invention is directed to multi-specific/multivalent molecules of novel formats. The molecules with the formats of the present invention have desired yield and thermostability. The present invention also includes methods of producing and using the molecules described herein.

6. 发明公开

EP2566894A1 COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES 审中-公开
标题翻译：组合物和使用的治疗抗体的多价LDL相关蛋白6方法（LRP6）
公开(公告)号：EP2566894A1
公开(公告)日：2013-03-13
申请号：EP11723308.0
申请日：2011-05-05
申请人： Novartis AG
发明人： CONG, Feng , ETTENBERG, Seth , JENKINS, David , LEI, Ming , LOEW, Andreas , VINCENT, Karen , ZHOU, Li
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00 , C07K16/46 , C12N15/113
CPC分类号： C07K16/2863 , A61K39/395 , A61K39/3955 , A61K2039/505 , C07K16/28 , C07K16/468 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/55 , C07K2317/622 , C07K2317/64 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof.

7. 发明公开

EP4056588A1 CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELL 审中-实审转让
公开(公告)号：EP4056588A1
公开(公告)日：2022-09-14
申请号：EP22162298.8
申请日：2016-04-08
申请人： Novartis AG , The Trustees of The University of Pennsylvania
发明人： BITTER, Hans , BORDEAUX, Jennifer Mary , BRANNETTI, Barbara , BROGDON, Jennifer , DAKAPPAGARI, Naveen Kumar , GILL, Saar , HIGHFILL, Steven , HUANG, Lu , JUNE, Carl H. , KIM, Ju Young , LEI, Ming , LI, Na , LOEW, Andreas , ORLANDO, Elena , RUELLA, Marco , TRAN, Thai , ZHANG, Jimin , ZHOU, Li
IPC分类号： C07K14/725 , C07K16/28 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

8. 发明授权

EP3119425B1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 有权转让
公开(公告)号：EP3119425B1
公开(公告)日：2020-09-23
申请号：EP15764851.0
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00

9. 发明公开

EP3280729A2 CD20 THERAPIES, CD22 THERAPIES, AND COMBINATION THERAPIES WITH A CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) - EXPRESSING CELL 有权转让
标题翻译： CD20疗法，CD22疗法和与CD19嵌合抗原接受者（CAR）的组合疗法 - 表达细胞
公开(公告)号：EP3280729A2
公开(公告)日：2018-02-14
申请号：EP16719611.2
申请日：2016-04-08
申请人： Novartis AG , The Trustees of The University of Pennsylvania
发明人： BITTER, Hans , BORDEAUX, Jennifer, Mary , BRANNETTI, Barbara , BROGDON, Jennifer , DAKAPPAGARI, Naveen, Kumar , GILL, Saar , HIGHFILL, Steven , HUANG, Lu , JUNE, Carl, H. , KIM, Ju, Young , LEI, Ming , LI, Na , LOEW, Andreas , ORLANDO, Elena , RUELLA, Marco , TRAN, Thai , ZHANG, Jimin , ZHOU, Li
IPC分类号： C07K14/725 , C07K16/28 , C12N5/0783 , A61K39/00
CPC分类号： C07K14/70596 , A61K38/00 , A61K39/0011 , A61K45/06 , A61K2039/5156 , A61K2039/5158 , A61K2039/70 , C07K14/7051 , C07K16/2803 , C07K16/2866 , C07K2317/24 , C07K2317/622 , C07K2319/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

10. 发明公开

EP3811970A1 REGULATABLE CHIMERIC ANTIGEN RECEPTOR 审中-实审转让
公开(公告)号：EP3811970A1
公开(公告)日：2021-04-28
申请号：EP20191324.1
申请日：2015-03-13
申请人： Novartis AG , The Trustees of The University of Pennsylvania , Engels, Boris
发明人： ENGELS, Boris , LOEW, Andreas , MILONE, Michael C. , ZHOU, Li
IPC分类号： A61K39/00 , A61K38/00
摘要： Provided are compositions and methods relating to regulatable chimeric antigen receptors (RCARs), natural killer cell receptor CARs (NKR-CARs), and regulatable NKR-CARs (RNKR-CARs), where the intracellular signaling or proliferation of the RCAR or RNKR-CAR can be controlled to optimize the use of an RCAR/NKR-CAR- or RNKR-CAR-expressing cell to provide an immune response. Cells can be engineered to express a RNKR-CAR or to express a RCAR and a NKR-CAR (e.g., inhibitory NKR-CAR). For example, a RCAR or RNKR-CAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR or RNKR-CAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式